持续性脾源性IgM优先识别凝血因子VIII A2和C2结构域表位但不改变抗体产生
本研究从免疫后凝血因子VIII敲除小鼠脾脏分离纯化单克隆抗体,用流体相酶联免疫吸附试验和计算对接模型分析IgM与凝血因子VIII的结合。鉴定出16株猪交叉反应性非抑制性凝血因子VIII特异性IgM单克隆抗体,其优先结合A2和C2结构域,但注射IgM或凝血因子VIII/IgM免疫复合物不影响新发凝血因子VIII抗体产生。
要点
- 鉴定出16株猪交叉反应性非抑制性凝血因子VIII特异性IgM单克隆抗体。
- IgM优先结合凝血因子VIII A2和C2结构域内K376、T381、K437、R2215或K2249残基。
- 注射IgM或凝血因子VIII/IgM免疫复合物不影响新发凝血因子VIII抗体产生。
核心结论
- 持续性凝血因子VIII特异性IgM为多克隆但优先结合A2和C2结构域。
- 凝血因子VIII/IgM免疫复合物形成不显著改变抑制物产生。
研究设计与样本
- 研究从免疫后凝血因子VIII敲除小鼠脾脏分离纯化单克隆抗体。
- 结合相互作用用新型流体相酶联免疫吸附试验和计算对接模型评估。
主要发现
- 鉴定出16株猪交叉反应性非抑制性凝血因子VIII特异性IgM单克隆抗体。
- RNA测序显示13个独特VDJ/VJ序列,提示来自13个独特B细胞克隆。
- IgM在体外和计算机模拟中显示对凝血因子VIII的多克隆和多反应性结合。
- 分子对接识别IgM频繁与A2和C2结构域内K376、T381、K437、R2215或K2249残基相互作用。
- 注射单个IgM或共注射凝血因子VIII/IgM免疫复合物不影响新发凝血因子VIII抗体产生。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The most significant treatment complication for patients with hemophilia A is the development of neutralizing immunoglobins (Igs) G, termed inhibitors, against factor VIII (FVIII), which prevent FVIII replacement therapy. Low titers of FVIII-specific IgMs have been identified in hemophilia A patients with and without inhibitors, as well as in healthy individuals. However, the duration and influence of IgMs on the immune response to FVIII remains unclear. OBJECTIVES: To characterize the binding interactions of persistently secreted FVIII-specific IgMs in hemophilia A mice and assess their effect on IgG antibody development. METHODS: Splenic-derived monoclonal antibodies (mAbs) from immunized FVIII knockout mice were isolated and purified using hybridoma technology. Binding interactions were assessed utilizing a novel fluid-phase enzyme-linked immunosorbent assay and computational modeling with High Ambiguity-Driven protein-protein DOCKing to account for weak IgM binding. RESULTS: Sixteen porcine cross-reactive and noninhibitory FVIII-specific IgM mAbs were identified. RNA sequencing of FVIII-specific IgMs revealed 13 unique variable, diversity, and joining (VDJ)/variable and joining (VJ) sequences indicating derivation from 13 unique B cell clones. The IgMs demonstrated polyclonal and polyreactive binding to FVIII in vitro and in silico. Molecular docking studies with reconstructed IgM variable, diversity, and joining/variable and joining regions identified frequent IgM interactions with amino acid residues K376, T381, K437, R2215, or K2249 within the FVIII A2 and C2 domains. Injections of individual IgMs prior to FVIII exposure and co-injection of FVIII/IgM immune complexes did not affect de novo FVIII antibody production. CONCLUSION: Persistent FVIII-specific IgMs are polyclonal but preferentially bind the A2 and C2 domains. FVIII/IgM immune complex formation does not significantly alter inhibitor development.
引用
- York ES, Dratch BD, Ito J, et al. Persistent splenic-derived IgMs preferentially recognize factor VIII A2 and C2 domain epitopes but do not alter antibody production. J Thromb Haemost. 2024. PMID: 39476969. doi:10.1016/j.jtha.2024.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。